Navigating the evolving role of real-world evidence in the Inflation Reduction Act: an interview with Paul Arora, University of Toronto

The Inflation Reduction Act (IRA) has introduced significant changes to the US healthcare system, particularly impacting pharmaceutical companies and their evidence requirements for Medicare price negotiations. To better understand the implications of these reforms, we speak with Paul Arora (University of Toronto), an author of the article ‘The Inflation Reduction Act: An Opportunity to Accelerate Confidence in US Real-World Evidence’ on the evolving role of real-world evidence (RWE), and the methodological challenges pharmaceutical companies must navigate to generate credible data for the new pricing process. Please could you introduce yourself and your background? I am an epidemiologist with a focus...